Alzheimer’s Disease: FDA Gives Full Approval to New Treatment Leqembi

When the FDA gave full (traditional) approval to Leqembi (generic name:
lecanemab), it wasn’t just another pharma headlineit was a clear signal that Alzheimer’s care is
stepping into a new era: one where we’re not only treating symptoms, but also trying to slow the disease process
itself.

Before anyone starts engraving “Cure Found!” on a trophy, though: Leqembi is not a cure. It won’t rewind time back
to “Where did I put my keys?” being the biggest mystery in the house. What it can dobased on a large clinical
trialis modestly slow cognitive and functional decline in people with
early Alzheimer’s disease. That “modestly” matters, because with Alzheimer’s, even small amounts
of time can be priceless.

This article breaks down what the FDA’s full approval means, who Leqembi is for (and who it isn’t), what the
evidence actually shows, the biggest safety concerns (hello, MRI appointments), and the real-world logisticslike
cost and Medicare coverage. And yes, we’ll keep it human. Alzheimer’s is heavy; your reading experience doesn’t
have to be.

Important note: This is educational information, not medical advice. Decisions about diagnosis and treatment should be made with a qualified clinician.

What “full approval” actually means (and why it’s different from “accelerated”)

Leqembi first entered the U.S. market through the FDA’s Accelerated Approval pathway, which can
allow earlier access to treatments for serious diseases when there’s an unmet need. Accelerated approval can be
based on a surrogate markersomething that’s strongly linked to clinical benefit. For Leqembi,
that surrogate was reducing amyloid plaques in the brain.

Full (traditional) approval is the FDA basically saying: “Show us the real-world meaningful partdoes it help
people function better or decline more slowly?” For Leqembi, the confirmatory data came from a large Phase 3 trial
that showed statistically significant slowing of decline in early Alzheimer’s disease.

Translation: this isn’t just “it changes a biomarker.” It’s “there’s evidence it changes the clinical course,”
even if the improvement is measured in inches, not miles.

Leqembi in plain English: what it is and how it works

A quick Alzheimer’s refresher: amyloid, tau, and the brain’s bad “glitter” problem

Alzheimer’s disease is a progressive brain disorder that gradually damages memory, thinking, and everyday
functioning. Scientists have long focused on two hallmark changes:
amyloid-beta plaques (protein clumps outside neurons) and tau tangles (twisted
fibers inside neurons). Think of amyloid as sticky glitter: it spreads, it clumps, and it’s annoyingly hard to
clean up once it’s everywhere.

Not every person’s Alzheimer’s is identical, and amyloid isn’t the whole story. But amyloid buildup is a major
part of the “classic” Alzheimer’s pathwayand that’s the pathway Leqembi targets.

So what does Leqembi do?

Leqembi is an amyloid beta–directed antibodya type of monoclonal antibody designed to bind to
amyloid beta and help clear it from the brain. In clinical studies, treatment reduced amyloid plaque levels and
was associated with less decline on cognitive and functional measures compared with placebo.

It’s a “disease-modifying” approach in the sense that it targets a biological feature of Alzheimer’s, rather than
only managing symptoms. But it’s still not magic. It’s more like tapping the brakes on a downhill slopenot
turning the car around.

Who Leqembi is for (and why “early” is doing a lot of work here)

The FDA-approved indication matters a lot: Leqembi is for Alzheimer’s disease, initiated in people with
mild cognitive impairment (MCI) or mild dementia stagethe group studied in trials. It’s not intended to
start in moderate or severe dementia stages.

Two must-haves before starting

• Early-stage clinical status: mild cognitive impairment due to Alzheimer’s or mild Alzheimer’s dementia.
• Confirmed amyloid pathology: you need evidence of amyloid in the brain before treatment starts.
  This is typically shown through an amyloid PET scan or cerebrospinal fluid (CSF) testing; availability varies by region and clinic.

That second point is huge. Leqembi isn’t a general “memory drug.” It’s meant for Alzheimer’s disease specifically,
and it works by targeting amyloidso clinicians need to confirm amyloid is actually involved before going forward.

A note on genetics: APOE ε4 and risk discussions

Many people have heard of APOE ε4 as a genetic risk factor for Alzheimer’s disease. In the context
of Leqembi, APOE ε4 is important for a different reason: people who carry APOE ε4especially those with two copies
(homozygotes)have a higher risk of certain brain imaging side effects (ARIA, explained below).
Because of that, clinicians may recommend genetic testing to inform shared decision-making.

Nobody should feel pressured into genetic testing “just because a drug exists.” It’s a personal decision with
emotional and family implications. The practical point is that it can help estimate risk and guide monitoring.

What the evidence shows: benefits without hype

The CLARITY-AD trial (the headline numbers)

In the key Phase 3 trial in early Alzheimer’s disease, people receiving lecanemab had
moderately less decline on a common global measure of cognition and function called the
Clinical Dementia Rating–Sum of Boxes (CDR-SB) over 18 months compared with placebo.

The often-cited figure: about 27% slowing of decline on CDR-SB over the study period. Another way
to say it: on average, the treatment group declined less than the placebo group. That difference is meaningful at
the population level, but it’s not a guarantee for any one person.

How to interpret “slowing” in real life

Here’s a practical way to think about it. Slowing decline doesn’t necessarily mean “better memory.” It can mean
more time staying in earlier stagesmore time managing daily routines, participating in
conversations, recognizing loved ones, or living more independently.

It also means expectations should be realistic. If someone is already in later-stage dementia, Leqembi isn’t
designed for that situation. And even in early-stage disease, the benefit is typically described as modest.
Families should weigh the potential upside against the monitoring burden and side-effect risk.

Risks and safety: ARIA, MRIs, and why this drug comes with a “serious business” vibe

Leqembi has a prominent safety issue called ARIA, short for
amyloid-related imaging abnormalities. You usually don’t “feel” ARIA the way you feel a fever or
a sore throat. It often shows up on MRIhence all the scanning.

ARIA 101

• ARIA-E: edema (swelling) or fluid buildup seen on MRI
• ARIA-H: small areas of bleeding or related changes seen on MRI

Many ARIA cases are asymptomatic, and many resolve over time, but seriousand in rare cases
life-threateningevents have been reported. That’s why this therapy is typically offered in settings prepared to
monitor and manage complications.

How common are side effects?

In the large Phase 3 study, the most common adverse reactions (more frequent than placebo) included
infusion-related reactions, ARIA-H, ARIA-E, and
headache. Infusion reactions were relatively common, and ARIA occurred at clinically meaningful
ratesespecially in higher-risk genetic groups.

MRI monitoring: yes, it’s part of the deal

Because ARIA is often detected on imaging before it causes noticeable symptoms, MRI monitoring is a standard part
of care. The FDA also recommended earlier MRI monitoring after reviewing safety data, adding an
MRI between the 2nd and 3rd infusion to catch early ARIA-E sooner.

Practically, that means baseline MRI plus scheduled follow-ups early in treatmentand urgent imaging if symptoms
suggest ARIA. In other words: if you hate MRI machines, you won’t love this process. But the scans are there for
a reason: safety.

Dosing and administration: infusions first, then maintenance options

Leqembi is typically started as an intravenous infusion every two weeks. After 18 months, the
prescribing information describes options: continue every two weeks or transition to a maintenance regimen.
Maintenance options include IV every four weeks or a subcutaneous weekly
maintenance dose (using an autoinjector), depending on clinician judgment, patient preference, and practical
considerations.

One important nuance: while modeling supports maintenance dosing strategies, long-term clinical outcome data for
some transitions may be more limited than for the original 18-month trial regimen. That doesn’t mean the
maintenance approach is “bad”it means the evidence base is evolving, and clinicians will tailor plans based on
emerging data and real-world experience.

Real-world logistics: what it takes to start Leqembi in the U.S.

Step 1: A careful diagnosis (because not all memory issues are Alzheimer’s)

Memory problems can come from many sourcessleep issues, medication side effects, depression, thyroid problems,
vitamin deficiencies, and more. A thorough workup matters. When Alzheimer’s is suspected, clinicians often use a
combination of cognitive testing, medical evaluation, and biomarker confirmation (like amyloid testing) to clarify
what’s going on.

Step 2: Amyloid confirmation

This is the “show your work” part. Because Leqembi targets amyloid, clinicians confirm amyloid pathology before
starting. The exact method depends on what’s available and appropriate for the person: imaging, CSF, or other
validated approaches as they become accessible.

Step 3: Building a monitoring plan

Treatment isn’t just “get the drug.” It’s: infusion scheduling, side-effect monitoring, MRI appointments, and a
plan for what to do if ARIA is detected. Many centers use structured protocolsoften aligned with published
appropriate-use recommendationsto standardize safety steps.

Cost and Medicare coverage: the part nobody wants to Google at 2 a.m.

Coverage and out-of-pocket costs can be complicated, but one big headline is that
Medicare coverage broadened after the FDA’s traditional approval, with an important condition:
collection of real-world data through a registry (often called “coverage with evidence development”).

CMS described key coverage criteria that include: being enrolled in Medicare, having a diagnosis consistent with
mild cognitive impairment or mild dementia due to Alzheimer’s disease, having documented evidence of beta-amyloid
plaque, and being treated by a clinician participating in a qualifying registry with appropriate follow-up care.

For people with Original Medicare, coinsurance may apply after the deductibleso families often need to discuss
costs with their plan, supplemental coverage, and care team. It’s not the fun part of medicine, but it is part of
reality.

How Leqembi fits into Alzheimer’s care: not either/or, but “and”

Even with disease-modifying therapy, Alzheimer’s care still includes:
managing symptoms, supporting caregivers, optimizing sleep, treating mood issues, addressing safety in the home,
and planning for the future. Current symptomatic medications (like cholinesterase inhibitors and memantine) may
still be used alongside Leqembi when appropriate.

It’s also important to keep the bigger picture in view: Alzheimer’s is common, and the U.S. burden continues to
grow with an aging population. New treatments bring hopebut also raise questions about access, capacity (MRI and
infusion infrastructure), and equity in who gets diagnosed early enough to qualify.

FAQs

Does Leqembi cure Alzheimer’s disease?

No. It is not a cure and does not restore the brain to “pre-Alzheimer’s” status. It may slow decline in early
Alzheimer’s disease for some people.

Who should not start Leqembi?

Leqembi is intended to be initiated in early Alzheimer’s (MCI or mild dementia stage) with confirmed amyloid
pathology. People outside that groupespecially those with more advanced dementiawere not the population studied
for initiation, and treatment decisions should be individualized by a clinician.

Why are there so many MRIs?

Because ARIA may appear on MRI before symptoms occur. Monitoring helps clinicians detect ARIA early and adjust
treatment to reduce risk.

If someone carries APOE ε4, does that mean they can’t take Leqembi?

Not necessarily. APOE ε4 status is mainly used to inform risk discussions and monitoring plans, since risk of
ARIA is higherespecially for people with two copies. Decisions should be made with a clinician after reviewing
risks and benefits.

Experiences from the real world: what families often report (and what surprises them)

Alzheimer’s headlines tend to sound clean and simple: “Drug approved!” Real life is… less like a headline and
more like a group project where nobody can find the shared document. Below are common experiences families and
patients often describe when navigating Leqembishared here as educational, composite examples, not as any one
person’s story.

1) The diagnosis process feels like a marathon with paperwork

Many families expect a single “memory test” and a quick yes/no. Instead, they often go through multiple visits:
primary care, neurology, cognitive testing, lab work, and then the big “amyloid confirmation” step. A common
emotional whiplash: relief that there’s a plan, mixed with frustration that the process takes timeespecially
when the whole point of Leqembi is that early matters.

2) “Wait, we need MRIs how often?” becomes a recurring plot twist

Families sometimes assume MRIs are a one-and-done screening. Then they learn the monitoring schedule, plus the
possibility of extra imaging if symptoms appear. People describe planning their calendars around infusion days and
MRI appointments the way others plan around weddings. (Except with less cake, more waiting-room coffee.)

The upside: many caregivers say the MRI schedule, while inconvenient, also provides reassurancelike a safety net
that helps everyone feel the treatment is being handled carefully.

3) Infusion day becomes strangely routine

After the first infusionwhich can come with nerves and “What if something happens?” energymany people settle
into a rhythm. Caregivers often pack snacks, a book, and a phone charger like they’re boarding a flight. Some
describe the infusion center as a quiet place where they meet other families who “get it” without needing a long
explanation.

Others find the routine emotionally tough: showing up every two weeks can feel like being reminded, over and over,
that Alzheimer’s is real. For those families, building in small rituals helpslike a favorite lunch afterward or a
short walksomething that says, “We’re still living life, not just managing appointments.”

4) The benefit can be subtleand that can be surprisingly hard

Families sometimes expect an obvious “before and after.” But slowing decline doesn’t always announce itself with
fireworks. Instead, caregivers might notice tiny things: fewer missed steps when cooking, a steadier ability to
follow a conversation, or fewer “off” days. Because the change is gradual, people sometimes wonder, “Is it doing
anything?” Clinicians may track changes over time using cognitive and functional measures to help ground the
conversation in something more objective than gut feeling.

5) Shared decision-making becomes the real treatment “core”

The most consistent experience families describe is that Leqembi decisions are rarely one-sided. People weigh
personal priorities: “Is the monitoring burden worth it for us?” “How do we feel about risk?” “Do we have the
support to get to appointments?” In many households, the conversation expands to include adult children,
caregivers, and sometimes close friendsbecause Alzheimer’s doesn’t stay neatly inside one person’s calendar.

A practical takeaway families often share: bring questions to appointments in writing. In the moment, it’s easy to
forget what you meant to ask. (Stress has a way of deleting your brain’s draft folder.) Asking about eligibility,
MRI schedule, side-effect warning signs, medication interactions, and cost/coverage details can make the path
clearer.

Conclusion

The FDA’s full approval of Leqembi marks a meaningful shift in Alzheimer’s care: a treatment aimed at slowing
early disease progression, backed by clinical trial evidencenot just biomarker changes. But it also comes with
real trade-offs: ARIA risk, MRI monitoring, infusion logistics, and access barriers that depend on healthcare
infrastructure and coverage rules.

For the right personearly in the disease, with confirmed amyloid pathology, and with a care team prepared to
monitor safetyLeqembi may offer something Alzheimer’s families value deeply: more time.
Not perfect time. Not easy time. But time with more independence, more clarity, and more moments that still feel
like “us.”